239 related articles for article (PubMed ID: 31561688)
21. Comparison of biofilm formation in clinical isolates of Candida species in a tertiary care center, North India.
Agwan V; Butola R; Madan M
Indian J Pathol Microbiol; 2015; 58(4):475-8. PubMed ID: 26549070
[TBL] [Abstract][Full Text] [Related]
22. Prevalence of albicans and non-albicans candiduria in a Malaysian medical centre.
Ding CH; Wahab AA; Muttaqillah NA; Tzar MN
J Pak Med Assoc; 2014 Dec; 64(12):1375-9. PubMed ID: 25842581
[TBL] [Abstract][Full Text] [Related]
23. Antifungal susceptibility profiles of bloodstream yeast isolates by Sensititre YeastOne over nine years at a large Italian teaching hospital.
Posteraro B; Spanu T; Fiori B; De Maio F; De Carolis E; Giaquinto A; Prete V; De Angelis G; Torelli R; D'Inzeo T; Vella A; De Luca A; Tumbarello M; Ricciardi W; Sanguinetti M
Antimicrob Agents Chemother; 2015 Jul; 59(7):3944-55. PubMed ID: 25896705
[TBL] [Abstract][Full Text] [Related]
24. A study on candiduria in neonates and infants from a tertiary care center, North India.
Yadav RK; Singh G; Kiran KS; Iram A; Rana B; Cs S; Xess I
Indian J Med Microbiol; 2023; 42():25-29. PubMed ID: 36967211
[TBL] [Abstract][Full Text] [Related]
25. Epidemiology of candidemia in Qatar, the Middle East: performance of MALDI-TOF MS for the identification of Candida species, species distribution, outcome, and susceptibility pattern.
Taj-Aldeen SJ; Kolecka A; Boesten R; Alolaqi A; Almaslamani M; Chandra P; Meis JF; Boekhout T
Infection; 2014 Apr; 42(2):393-404. PubMed ID: 24352810
[TBL] [Abstract][Full Text] [Related]
26. [Molecular epidemiology and antifungal susceptibility of Candida species isolated from urine samples of patients in intensive care unit].
Yüksekkaya S; Fındık D; Arslan U
Mikrobiyol Bul; 2011 Jan; 45(1):137-49. PubMed ID: 21341168
[TBL] [Abstract][Full Text] [Related]
27. [Comparison of Clinical Laboratory Standards Institute (CLSI) and European Committee on Antimicrobial Susceptibility Testing (EUCAST) broth microdilution methods for determining the susceptibilities of Candida isolates].
Dalyan Cilo B; Topaç T; Ağca H; Sağlam S; Efe K; Ener B
Mikrobiyol Bul; 2018 Jan; 52(1):35-48. PubMed ID: 29642828
[TBL] [Abstract][Full Text] [Related]
28. [In vitro activities of posaconazole, fluconazole, itraconazole, ketoconazole and voriconazole against Candida glabrata].
Blanco MT; Cañadas J; García-Martos P; Marín P; García-Tapia A; Rodríguez J
Rev Esp Quimioter; 2009 Sep; 22(3):139-43. PubMed ID: 19662547
[TBL] [Abstract][Full Text] [Related]
29. In vitro susceptibility of 245 yeast isolates to amphotericin B, 5-fluorocytosine, ketoconazole, fluconazole and itraconazole.
Martín E; Parras P; Lozano MC
Chemotherapy; 1992; 38(5):335-9. PubMed ID: 1337508
[TBL] [Abstract][Full Text] [Related]
30. [Biofilm production and antifungal susceptibility patterns of Candida species].
Yücesoy M; Karaman M
Mikrobiyol Bul; 2004; 38(1-2):91-8. PubMed ID: 15293907
[TBL] [Abstract][Full Text] [Related]
31. Prevalence and antifungal susceptibility of Candida species in a tertiary care hospital in Islamabad, Pakistan.
Tasneem U; Siddiqui MT; Faryal R; Shah AA
J Pak Med Assoc; 2017 Jul; 67(7):986-991. PubMed ID: 28770873
[TBL] [Abstract][Full Text] [Related]
32. Epidemiology of candidemia in Shiraz, southern Iran: A prospective multicenter study (2016-2018).
Arastehfar A; Yazdanpanah S; Bakhtiari M; Fang W; Pan W; Mahmoudi S; Pakshir K; Daneshnia F; Boekhout T; Ilkit M; Perlin DS; Zomorodian K; Zand F
Med Mycol; 2021 May; 59(5):422-430. PubMed ID: 32692816
[TBL] [Abstract][Full Text] [Related]
33. Anti-fungal susceptibility and virulence factors of Candida spp. isolated from blood cultures.
Sriphannam C; Nuanmuang N; Saengsawang K; Amornthipayawong D; Kummasook A
J Mycol Med; 2019 Dec; 29(4):325-330. PubMed ID: 31447236
[TBL] [Abstract][Full Text] [Related]
34. Relevance of antifungal penetration in biofilm-associated resistance of Candida albicans and non-albicans Candida species.
Singh R; Kumari A; Kaur K; Sethi P; Chakrabarti A
J Med Microbiol; 2018 Jul; 67(7):922-926. PubMed ID: 29767615
[TBL] [Abstract][Full Text] [Related]
35. Antifungal susceptibility testing results of New Zealand yeast isolates, 2001-2015: Impact of recent CLSI breakpoints and epidemiological cut-off values for Candida and other yeast species.
Morris AJ; Rogers K; McKinney WP; Roberts SA; Freeman JT
J Glob Antimicrob Resist; 2018 Sep; 14():72-77. PubMed ID: 29486358
[TBL] [Abstract][Full Text] [Related]
36. Identification, antifungal resistance profile, in vitro biofilm formation and ultrastructural characteristics of Candida species isolated from diabetic foot patients in Northern India.
Kumar D; Banerjee T; Chakravarty J; Singh SK; Dwivedi A; Tilak R
Indian J Med Microbiol; 2016; 34(3):308-14. PubMed ID: 27514952
[TBL] [Abstract][Full Text] [Related]
37. Biofilm-forming capacity of blood-borne Candida albicans strains and effects of antifungal agents.
Turan H; Demirbilek M
Rev Argent Microbiol; 2018; 50(1):62-69. PubMed ID: 28988900
[TBL] [Abstract][Full Text] [Related]
38. In vitro antifungal susceptibilities of Candida isolates from patients with invasive candidiasis in Kuala Lumpur Hospital, Malaysia.
Amran F; Aziz MN; Ibrahim HM; Atiqah NH; Parameswari S; Hafiza MR; Ifwat M
J Med Microbiol; 2011 Sep; 60(Pt 9):1312-1316. PubMed ID: 21459913
[TBL] [Abstract][Full Text] [Related]
39. [Biofilm production and antifungal susceptibility patterns of Candida species isolated from hospitalized patients].
Demirbileki M; Timurkaynak F; Can F; Azap O; Arslan H
Mikrobiyol Bul; 2007 Apr; 41(2):261-9. PubMed ID: 17682713
[TBL] [Abstract][Full Text] [Related]
40. Candida blood stream infections observed between 2011 and 2016 in a large Italian University Hospital: A time-based retrospective analysis on epidemiology, biofilm production, antifungal agents consumption and drug-susceptibility.
Brunetti G; Navazio AS; Giuliani A; Giordano A; Proli EM; Antonelli G; Raponi G
PLoS One; 2019; 14(11):e0224678. PubMed ID: 31697722
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
